Biochem/physiol Actions

Reversible: yes

Target IC₅₀: 300 nM and 200 nM for IRAK-1 and -4

Primary TargetIRAK-1/4

General description

A cell-permeable benzimidazole compound that acts as a potent and selective inhibitor of interleukin-1 receptor-associated kinases (IC₅₀ = 300 nM and 200 nM for IRAK-1 and -4). Shown to exhibit little activity against a panel of 27 other kinases (IC₅₀ >10 µM), including lck and src. The solid form of this compound (Cat. No. 407601) is also available.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Srivastava, R., et al. 2012. Cancer Res.72, In press.Bhattacharyya, S., et al. 2007. Am. J. Physiol. Gastrointest. Liver Physiol.293, G429.Powers, J.P., et al. 2006. Bioorg. Med. Chem. Lett.16, 2842.

Packaging

5 mg in Glass bottle

Packaged under inert gas

Physical form

A 25 mM (5 mg/506 µL) solution of Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor (Cat. No. 407601) in DMSO.

Reconstitution

Following initial thaw, aliquot and freeze (-70°C). Aliquots are stable for up to 6 months at -70°C.

Warning

Toxicity: Irritant (B)